Celularity Inc.

CELU

US1511902041

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
3.38 ^USD	+5.30%		+2.11%	+36.62%

Mar. 26	Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	CI
Mar. 20	Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	MT

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Celularity Inc.

Celularity Receives Healthcare Common Procedure Coding System Q Code Approval from the U.S. Centers for Medicare & Medicaid Services for Biovance 3L	Mar. 26	CI
Celularity Seeks FDA Orphan Drug Status for PDA-002 in Facioscapulohumeral Muscular Dystrophy	Mar. 20	MT
Celularity Inc. announced that it expects to receive $10 million in funding from Yorkville Advisors Global LP	Mar. 12	CI
Celularity to Execute Reverse Stock Split Next Week	Feb. 23	MT
Celularity Inc. Provides Sales Guidance for the First Quarter and Full Year 2024	Feb. 01	CI
Celularity Insider Bought Shares Worth $5,331,335, According to a Recent SEC Filing	Jan. 17	MT
Genting Berhad Engages in Discussions with Celularity Inc	Jan. 17	CI
Celularity Inc. announced that it has received $6 million in funding from Dragasac Limited	Jan. 15	CI
Celularity Inc. announced that it expects to receive $6 million in funding from Dragasac Limited	Jan. 11	CI
Celularity, BioCellgraft Strike Deal for Placental-Derived Biomaterial Products	Jan. 04	MT
Celularity Inc. Confirms Commercialization Agreement with BioCellgraft, Inc. for Manufacture and Distribution of Advanced Biomaterial Products for Use in Oral Healthcare	Jan. 04	CI
Celularity Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2023	Jan. 03	CI
North American Morning Briefing : Stock Futures Extend Losses as FOMC Minutes Awaited	Jan. 03	DJ
Celularity Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Jan. 03	CI
Celularity Inc. Announces Resignation of Robin L. Smith, MD, from Board of Directors	Dec. 29	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
North American Morning Briefing : Traders Await FOMC, Powell	Dec. 13	DJ
North American Morning Briefing : Stock Futures Rise With More Jobs Data on Tap	Dec. 06	DJ
Celularity Receives Non-Compliance Notice From Nasdaq	Nov. 24	MT
North American Morning Briefing : Stock Futures Muted; Nvidia Slips in Offhours Trading	Nov. 22	DJ
Lim Kok Thay Notifies Celularity Inc. of His Intention to Resign as a Member of the Board and All Committees	23-09-19	CI
Celularity Inc.(NasdaqCM:CELU) dropped from S&P Global BMI Index	23-09-18	CI
Celularity Inc. Appoints Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors	23-09-07	CI
Celularity to Support Research of Regeneron's Allogeneic Cell Therapy Candidates for Solid Tumors	23-08-29	MT
Celularity Inc Announces Multi-Year Research Collaboration Services Agreement with Regeneron Pharmaceuticals, Inc	23-08-29	CI

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohnâs disease.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - ASGCT Meeting

More about the company

	1st Jan change	Capi.
CELULARITY INC.	+36.62%	69.92M
VERTEX PHARMACEUTICALS INCORPORATED	-1.51%	105B
REGENERON PHARMACEUTICALS, INC.	+3.22%	97.5B
ARGENX SE	+1.86%	22.19B
BIONTECH SE	-16.53%	21.33B
GENMAB A/S	-8.49%	18.68B
WUXI APPTEC CO., LTD.	-42.33%	16.6B
BEIGENE, LTD.	-20.09%	14.52B
NEUROCRINE BIOSCIENCES, INC.	+5.47%	14.09B
SAREPTA THERAPEUTICS, INC.	+28.85%	10.99B